236 Users Online
Ineffective Esophageal Motility Treatment Market by Product (Devices and Drugs)
The global revenue from the Ineffective Esophageal Motility Treatment Market was around US$ 3.95 Billion in 2022, with the global market expected to grow at a CAGR of 5.9% to reach a valuation of about US$ 7.47 Billion by the end of 2033.
Market Size (2023)
US$ 4.21 Billion
Projected Market Value (2033)
US$ 7.47 Billion
Global Market Growth Rate (2023 to 2033)
Market Share of Top 5 Countries
As assessed by Persistence Market Research, drugs segment held around 97.6% in the global market, in 2022. The global ineffective esophageal motility treatment market holds nearly 23.1% revenue share of the global ENT treatment market valued at US$ 17.12 Billion in 2022.
The global market recorded a historic CAGR of 5.4% in the last 7 years from 2015 to 2022.
The global market is likely to show high growth over the coming years at a CAGR of 5.9% and reach a global market size of 7.47 Billion by 2033.
Increasing prevalence of GERD, also known as gastroesophageal reflux disease has been one of the main factors responsible for the growth of ineffective esophageal motility treatment market over the years.
Regurgitation and heartburn are two common symptoms of gastroesophageal reflux disease (GERD). A common medical disorder called asthma often co-occurs with gastroesophageal reflux disease. Asthma and gastroesophageal reflux have complicated relationships and interactions that may make asthma symptoms more common, and cause or exacerbate GERD. Persons with asthma frequently have higher rates of GERD symptoms when compared to the general population.
The effectiveness of various gastroesophageal reflux treatment methods and devices has been investigated in several research and clinical trials. Clinical studies have aided patients in getting a clear view of the situation and making better treatment decisions for gastroesophageal reflux disease, and this creates a growth opportunity for the market.
Rising treatment demand for gastrointestinal problems, dysphagia, GERD, burning chest discomfort, and achalasia, as well as an ageing population has caused the global market for ineffective esophageal motility treatment to expand.
Both emerging markets and developed economies would experience faster growth throughout the projected period in the market for ineffective esophageal motility treatments.
Key manufactures are also involved in the activities to tackle such disorders.
“Increasing Prevalence of GERD, Hiatal Hernia and Abdominal Obesity”
Obesity, or excess belly fat, has been identified as being one of the leading causes of gastroesophageal reflux disease in several studies.
Obesity is a complicated disease with high mortality and morbidity. Obesity is frequently associated with gastroesophageal reflux disease (GERD), which strikes 20% of adults in the United States of America.
Another key factor propelling the market for ineffective esophageal motility treatments is the growing elderly population. Due to issues with esophageal motility and decreased saliva production, esophageal acid clearance may be reduced in the elderly. Age-related declines in salivary production lead to a markedly reduced response of salivary bicarbonate to esophageal acid perfusion.
Dysphagia and trouble swallowing are among the typical symptoms experienced by the ageing population. They are connected to a number of illnesses that affect the elderly more frequently, such as oropharyngeal dysphagia, Parkinson's disease, cerebrovascular disease, and diabetes.
The emergence of acid reflux and the transformation of acid reflux into the chronic condition known as gastroesophageal reflux are both significantly influenced by hiatal hernia. Lower esophageal sphincter weakness brought on by a hiatal hernia might result in stomach contents backing up into the esophagus. A hiatal hernia occurs when a small gap in the diaphragm allows a part of the stomach to push through. Hiatal hernia may result from the existence of weakened supporting tissues.
Many patients are underserved in emerging economies, including South Africa, Brazil, China, Mexico, Brazil, and India. Medical device businesses have a great opportunity in these regions. Patient disposable income and economic gain in these emerging nations will contribute to the market's long-term viability. Similarly, increased medical infrastructure and medical investment by various governments would enable the installation and usage of advanced medical equipment in healthcare institutions such as hospitals.
“Adverse Effects of Surgical Treatment and High Treatment Cost”
Anti-reflux fundoplication procedures generally have obstructive mechanical side effects. A number of patients experience difficulty swallowing. Another adverse effect associated with anti-reflux fundoplication is the difficulty in passing air from the stomach, which makes it difficult to burp, thus causing more gas to pass through the intestine. This results in bloating.
The market for ineffective esophageal motility treatment is predicted to rise slowly because of the high price of gastroscopes and esophagoscopes as well as the threat of infection. One of the sections of medical equipment that is frequently linked to the development of healthcare infections is contaminated endoscopes. Before storing, esophagoscopes and gastroscopes must be thoroughly cleaned and dried.
Since most endoscopes used in gastroenterology have numerous channels and are not heat sterilized, they are challenging to clean. They are also exceedingly difficult to clean and have limited lumens. Blood, bodily fluids, and other microorganisms are expected to be heavily present on these devices.
The clinical success rate of surgical devices for gastroesophageal reflux disease treatment is very low. This factor might hamper the global market growth over the forecast duration.
Why is the United States Market Booming?
“Rising Obese Population Leading to the GERD Induced Injuries in the Country.”
The United States accounted for around 43.1% market share in the global market in 2022.
Obesity may increase the risk of esophageal cancer and inflammation through mechanisms unrelated to reflux, and it may make the esophageal mucosa particularly vulnerable to damage from GERD.
The market is driven by esophageal injuries, which could result from an increased prevalence of obesity.
Will China Be a Lucrative Market for Ineffective Esophageal Motility Treatment?
“Growing Prevalence of Dysphagia”
The China market held around 7.0% share of the global market in 2022.
Dysphagia is becoming more common in China, especially among the elderly and those who have had strokes. As people age and have more illnesses, the prevalence of dysphagia continuously rises.
How is Germany Emerging as a Prominent Market?
“Rising Cases of Esophageal Disorders.”
Germany held a market share of about 5.7% of the global market in 2022.
The increasing consumption of beverages like alcohol and coffee is leading to an increase in esophageal disorders in the country. Such beverages develop acid reflux symptoms, or a heartburn, a chronic symptom for GERD. This will fuel the market for esophageal motility treatment in Germany.
Which Product is Driving Demand within the Global Market?
“Effectiveness, Safety, and Accessibility as Over-the-counter Medications.”
The drugs segment held around 97.6% share of the total market in 2022.
One or more of the classic signs of gastroesophageal reflux include acid regurgitation and heartburn. Due to their effectiveness, safety, and accessibility as over-the-counter drugs, drugs like anticholinergics, nitrates, calcium channel blockers, beta-blockers, and phosphodiesterase inhibitors are still frequently used to treat the symptoms of gastric reflux despite the wide range of therapeutic options available. The symptoms of heartburn, hyperacidity, acid indigestion, GERD, and an upset stomach are alleviated with antacids.
Which Indication Drives High Demand For Ineffective Esophageal Motility Treatment?
“Changes in Patients' Lifestyles are Hastening the Onset of GERD”
GERD segment held around 45.6% share of the total market in 2022.
A persistent digestive illness called gastroesophageal reflux disease is defined by the vomiting of contents from the stomach into the esophagus. The increase in GERD prevalence is due to consumption of certain types of food and drinks, smoking and lack of physical activities.
Why Retail Sales Is Dominating the Global Market?
“Easy Availability of Drugs in Retail Pharmacies”
Retail sales held around 79.7% of the total market share in 2022.
When stomach acid leaks back up into the esophagus or food pipe, it is known as "acid reflux," a problem that affects many people. As a result, the person experiences heartburn, a burning discomfort in the lower chest area.
In retail pharmacies, there are numerous OTC products available to address the signs and symptoms of GERD. H2 blockers, antacids, prokinetics, and proton pump inhibitors are few of them that are attracting customers, thus propelling growth in the retail sales segment.
To increase ineffective esophageal motility treatment offerings and strengthen consumer base, the market players are involved in activities like increased clinical trials and product certification as well as product launches. Also, key market players in the industry are focusing on their distribution channels to expand their geographic reach.
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the ineffective esophageal motility treatment market, which are available in the full report.
2023 to 2033
Historical Data Available for
2015 to 2022
Key Countries Covered
Key Market Segments Covered
Key Companies Covered
Customization & Pricing
Available upon Request
The global market is currently valued at around US$ 3.95 Billion in 2022.
The global market estimates for 2023 is around US$ 4.21 Billion.
The global market is set to reach a valuation of around US$ 7.47 Billion by the end of 2033.
Sales of the market are set to witness growth at a CAGR of 5.9% between 2023 and 2033.
Demand for the global market increased at 5.4% CAGR from 2015–2022.
The U.S., China, Germany, France, and India account for around 65.0% of revenue share globally.
The U.S. accounts for around 43.1% share of the global market in 2022.
The China ineffective esophageal motility treatment market held around 7.0% market share in 2022.
The ineffective esophageal motility treatment market in Germany held around 5.7% market share in 2022.